Aortic Valve Stenosis Clinical Trials

• Adult male or female at least 50 years of age

• Has moderate CAVS as defined by:

‣ An AVA of ≥1.0 cm2 to ≤1.50 cm2

⁃ An AVC score between \>300 to 1200 Agatston units (AU) for women and between \>300 to 2000 AU for men

• Has a left ventricular ejection fraction (EF) of ≥45% at the time of Screening as determined by the echocardiography Imaging Core Laboratory

• For participants in CPET sub-study in Part A and all participants in Part B: If on beta blockade, the dose must be stable for at least 90 days prior to the Screening Visit with no anticipated changes during the study